PSYREFLECT

Issue #34

April 30, 2026

#1Research

One Dose of LSD for Generalised Anxiety: What the JAMA Phase 2b Actually Showed

Two doses worked, two did not — and the 92.5% rate of visual perceptual changes is not a side effect of the treatment, it is the treatment, which is exactly why outpatient pharmacotherapy framing does not apply.

psychedelic therapyanxietyGADLSD
3 minRead analysis
#2Research

One Question About Suicidality, 9.5 Years of Mortality: What a Korean National Cohort Tells Us

A self-reported "yes" to seriously considering suicide is not an event — it is a trait that predicts how a person dies for at least a decade.

suicidologysuicide-mortalitycohort-studyscreening
2 minRead analysis
#3Tool

PBS-5: a five-item screen for non-substance addictive behaviours, anchored to ICD-11

A five-minute, ICD-11-anchored screen across all five behavioural addictions — the right resolution for a 50-minute first session.

behavioral-addictionscreeningICD-11gambling
3 minRead analysis
#4Industry

Australia's Authorised Prescriber Scheme: What 134 Patients Reveal About a Real-World Psychedelic Programme

Australia's first 21 months of regulated psychedelic therapy show what the bottleneck actually is — psychiatrist and therapist time, not the molecule.

psychedelic-therapyregulationAustraliaMDMA
3 minRead analysis
#5Industry

India's Tele-MANAS at year three: 3.4 million calls, 53 cells, and the unfinished business of the treatment gap

Tele-MANAS proves the architecture works at national scale; whether it closes the treatment gap is a question outcome data, not call volume, will answer.

indiatele-manasmental-health-policytelehealth
3 minRead analysis
#6Resource

CIIS Psychedelic-Assisted Therapies Certificate: 2026-2027 Cohort Now Open

Treat psychedelic training as scaffolding for integration practice and trial work — not as a credential that creates a new clinical permission you do not otherwise have.

psychedelic therapytrainingcertificationMDMA
3 minRead analysis